NCT06777680View on ClinicalTrials.gov

Palmitoylethanolamide and Luteolin in Patients with Acute Ischemic Stroke

NANot yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Acute Ischemic Stroke AIS
Interventions
DIETARY_SUPPLEMENT

co-ultramicronized Palmitoylethanolamide + Luteolin (770 mg)

oral suspension, 10 ml twice a day (every 12 hours) for 7 days

OTHER

Placebo

oral suspension,10 ml twice a day (every 12 hours) for 7 days

PROCEDURE

Thrombectomy

Endovascular Thrombectomy in all eligible patients, according to national acute stroke treatment guidelines

Trial Locations (1)

Unknown

Azienda Sanitaria Universitaria Giuliano Isontina, Trieste

All Listed Sponsors
lead

Ospedali Riuniti Trieste

OTHER

NCT06777680 - Palmitoylethanolamide and Luteolin in Patients with Acute Ischemic Stroke | Biotech Hunter | Biotech Hunter